Febuxostat and Eosinophilia - a phase IV clinical study of FDA data

Summary:

Eosinophilia is reported as a side effect among people who take Febuxostat (febuxostat), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Zopiclone, and have Cardiac failure.

The phase IV clinical study analyzes which people have Eosinophilia when taking Febuxostat. It is created by eHealthMe based on reports of 9,653 people who have side effects when taking Febuxostat from the FDA, and is updated regularly.

What is Febuxostat?

Febuxostat has active ingredients of febuxostat. eHealthMe is studying from 9,693 Febuxostat users. Check the latest studies of Febuxostat.

What is Eosinophilia?

Eosinophilia (eosinophil count in the peripheral blood exceeds) is found to be associated with 956 drugs and 1,398 conditions by eHealthMe. Check the latest studies of Eosinophilia.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 28, 2026

9,653 people reported to have side effects when taking Febuxostat.
Among them, 39 people (0.4%) have Eosinophilia.

Among these 39 people:

How long have people been on Febuxostat when they have Eosinophilia? *

What is the gender of people who have Eosinophilia when taking Febuxostat? *

female: 40.62 %
male: 59.38 %

What is the age of people who have Eosinophilia when taking Febuxostat? *

What are other drugs people take besides Febuxostat? *

What are other side effects people have besides Eosinophilia? *

Rashes (redness): 18 people, 46.15%
Drug Ineffective: 11 people, 28.21%
Hepatic Mass: 11 people, 28.21%
Fever: 11 people, 28.21%
Myopathy (a muscular disease in which the muscle fibres do not function): 10 people, 25.64%
Itching: 6 people, 15.38%
Thrombocytopenia (decrease of platelets in blood): 3 people, 7.69%
Septic Shock (shock due to blood infection): 3 people, 7.69%
Drug Hypersensitivity: 2 people, 5.13%
Hypotension (abnormally low blood pressure): 2 people, 5.13%

What are the existing conditions these people have? *

Enlarged Prostate: 12 people, 30.77%
Cardiomyopathy (weakening of the heart muscle): 12 people, 30.77%
Cardiac Failure: 12 people, 30.77%
Myopathy (a muscular disease in which the muscle fibres do not function): 9 people, 23.08%
Dyslipidaemia (abnormal amount of lipids): 6 people, 15.38%
Gout (uric acid crystals building up in the body): 2 people, 5.13%
Burkitt Lymphoma (cancer of the lymphatic system): 2 people, 5.13%
Systemic Candida (whole body fungal infection): 1 person, 2.56%
Myositis (inflammation of the muscles): 1 person, 2.56%
Lung Cancer - Non-Small Cell (lung cancer): 1 person, 2.56%

* Approximation only. Some reports may have incomplete information.

Do you take Febuxostat and have Eosinophilia?

- Check whether Eosinophilia is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Febuxostat:

Febuxostat (9,693 reports)

Eosinophilia treatments and more:

Eosinophilia (20,276 reports)

Browse all side effects of Febuxostat:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Eosinophilia:

Eosinophilia (956 drugs)

Browse all the conditions that are associated with Eosinophilia:

Eosinophilia (1,398 conditions)

Related publications that referenced our studies

Azuma N, Matsui K, Hashimoto N, Yoshikawa T, Sano H, "Successful Switch to Golimumab for Eosinophilia and Skin Symptoms Related to Multiple Biologics in a Patient with Rheumatoid Arthritis", Internal Medicine, 2017 Jun .
Chiriac A, Brzezinski P, Stolnicu S, Podoleanu C, Moldovan C, Molnar C, Taranu T, "Eosinophilia–A rare possible adverse reaction during anti-tumor necrosis factor-alpha therapy for psoriasis", Journal of Dermatological Treatment, 2016 Mar .
Guidelli GM, Tenti S, Fioravanti A, "Severe eosinophilia during anti-tumor necrosis factor-alpha therapy for psoriatic arthritis", Indian Journal of Dermatology, Venereology, and Leprology, 2015 Jan .
Malisiewicz B, Murer C, Schmid JP, French LE, Schmid-Grendelmeier P, Navarini AA, "Eosinophilia during psoriasis treatment with TNF antagonists", Dermatology, 2013 Jan .
Azuma N, Matsui K, Hashimoto N, Yoshikawa T, Sano H, "Successful Switch to Golimumab for Eosinophilia and Skin Symptoms Related to Multiple Biologics in a Patient with Rheumatoid Arthritis", Internal Medicine, 2017 Jun .
Chiriac A, Brzezinski P, Stolnicu S, Podoleanu C, Moldovan C, Molnar C, Taranu T, "Eosinophilia–A rare possible adverse reaction during anti-tumor necrosis factor-alpha therapy for psoriasis", Journal of Dermatological Treatment, 2016 Mar .
Guidelli GM, Tenti S, Fioravanti A, "Severe eosinophilia during anti-tumor necrosis factor-alpha therapy for psoriatic arthritis", Indian Journal of Dermatology, Venereology, and Leprology, 2015 Jan .
Malisiewicz B, Murer C, Schmid JP, French LE, Schmid-Grendelmeier P, Navarini AA, "Eosinophilia during psoriasis treatment with TNF antagonists", Dermatology, 2013 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on febuxostat (the active ingredients of Febuxostat) and Febuxostat (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.